Shire PLC (SHP)

London
4,690.00
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    4,650.00 - 4,720.00

SHP Overview

Prev. Close
4,579
Day's Range
4,650-4,720
Revenue
12.29B
Open
4,575
52 wk Range
0-0
EPS
2.07
Volume
0
Market Cap
943.57M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
3,208,902
P/E Ratio
22.56
Beta
1.28
1-Year Change
0%
Shares Outstanding
142,965,031
Next Earnings Date
-
What is your sentiment on Shire?
or
Market is currently closed. Voting is open during market hours.

Shire PLC News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Shire PLC Analysis

Shire PLC Company Profile

Shire PLC Company Profile

Employees
23044

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company’s marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. The company was founded in 1986 and is headquartered in Dublin, Ireland. Shire plc is a subsidiary of Takeda Pharmaceutical Company Limited.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsBuyBuyStrong BuyStrong BuyBuy
SummaryBuyStrong BuyStrong BuyStrong BuyStrong Buy
  • HI, It seems the company is doing quite well.  Any expectation in 5/8 months?
    0
    • BUY SIGNAL 13/4/17
      0
      • There is 75% probability that the numbers tomorrow will beat estimates
        0